Does Anthem (Elevance Health) Cover Lantus?

Anthem's Current Formulary Placement for Lantus

Anthem (Elevance Health) lists Lantus on most commercial formularies as a non-preferred brand insulin, placing it at Tier 3 in the standard three-tier or four-tier structure. This means Lantus is covered, but patients pay a higher copay or coinsurance compared to preferred alternatives. Anthem's preferred long-acting insulin options typically include biosimilar insulin glargine products such as Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr).

The distinction between preferred and non-preferred matters financially. A Tier 2 preferred brand copay on a typical Anthem commercial plan runs $30 to $50 per fill, while a Tier 3 non-preferred brand copay can range from $60 to $100 or require 30% to 40% coinsurance 1. For patients stabilized on Lantus who want to remain on the branded product, this tier gap creates a meaningful cost difference over 12 months. The FDA has confirmed that approved biosimilar insulin glargine products meet rigorous standards for similarity to the reference product 2, which is why Anthem and other large insurers have shifted formulary preference toward these lower-cost alternatives.

Anthem plan designs vary by employer group and state. Some self-funded employer plans administered by Anthem may place Lantus at a different tier or waive step therapy entirely. Patients should verify their specific plan's drug list through the Anthem member portal or by calling the number on their insurance card.

Prior Authorization Requirements

Anthem requires prior authorization for Lantus on most commercial plans, and the process carries a moderate difficulty rating. The PA request asks the prescriber to document a diagnosis of type 1 or type 2 diabetes, current A1C level, and the clinical reason for choosing branded Lantus over a preferred biosimilar alternative.

The standard PA criteria include three main checkpoints. First, the patient must have a confirmed diabetes diagnosis with supporting lab work. Second, Anthem expects documentation showing the patient tried or has a contraindication to at least one preferred biosimilar insulin glargine. Third, the prescriber must explain why Lantus specifically is medically necessary for this patient 3. Reasons Anthem generally accepts include documented adverse reactions to biosimilar products, device-specific needs (such as the SoloStar pen), and physician-documented clinical instability during a prior switch attempt.

Turnaround time for a standard PA is 5 to 7 business days. Urgent PAs, which apply when a patient would face serious harm without the medication, receive a 24 to 72 hour review window. Dr. Irl Hirsch, professor of medicine at the University of Washington, has noted: "Switching a patient's insulin formulation for non-medical reasons introduces unnecessary glycemic variability, and the prior authorization process should account for this clinical reality" 4.

Prescribers can submit PA requests through Anthem's online provider portal, by fax, or through electronic PA platforms like CoverMyMeds. The most common reason for PA denial is incomplete documentation rather than outright clinical rejection.

Step Therapy: What Anthem Requires Before Approving Lantus

Anthem's step therapy protocol for Lantus requires patients to try a preferred biosimilar insulin glargine before the plan will authorize the branded product. This is a single-step edit. The patient does not need to fail multiple drugs.

The practical sequence works as follows. A prescriber writes for Lantus, and the pharmacy submits the claim. Anthem's system rejects the claim with a step therapy edit, directing the patient to a preferred biosimilar. The patient then fills the biosimilar and uses it for a plan-defined trial period, typically 60 to 90 days. If the biosimilar causes adverse effects, does not maintain glycemic control, or is otherwise unsuitable, the prescriber submits a PA with clinical documentation of the trial failure. Anthem reviews and, if approved, authorizes Lantus.

The American Diabetes Association's Standards of Care (2024) states: "Insulin regimens should be individualized based on the patient's needs, and non-medical switching of insulin products should be minimized to reduce the risk of hypoglycemia and glycemic instability" 5. This ADA position supports step therapy override requests when clinical documentation shows a biosimilar trial caused problems.

Patients with type 1 diabetes may have an easier time obtaining a step therapy override. The clinical rationale is straightforward: type 1 patients depend entirely on exogenous insulin, and any disruption in glycemic control carries immediate safety consequences. The ORIGIN trial (N=12,537) demonstrated that insulin glargine maintained stable fasting glucose levels over a median 6.2-year follow-up with a neutral cardiovascular safety profile 6, data that applies equally to the branded and biosimilar versions but underscores the importance of maintaining the specific product that achieves stability for a given patient.

How to Appeal a Denied Lantus Claim with Anthem

An Anthem denial of Lantus coverage triggers a structured appeal process with two internal levels and one external option. The first step is an internal appeal filed within 180 days of the denial notice.

For the first-level internal appeal, the prescriber or patient submits a written request explaining why Lantus is medically necessary. This letter should include the patient's diabetes diagnosis, current and historical A1C values, documentation of any biosimilar trial and its outcome, and any relevant clinical notes about adverse reactions or glycemic instability. Anthem reviews first-level appeals within 30 calendar days for non-urgent cases and within 72 hours for urgent cases 7.

If the first-level appeal is denied, patients can request a second-level internal review. This review is conducted by a physician who did not participate in the original denial decision. Including peer-reviewed literature supporting the clinical rationale strengthens the appeal. The ORIGIN trial data showing long-term safety and efficacy of insulin glargine, along with any patient-specific clinical evidence, should be referenced 6.

After exhausting internal appeals, patients in most states can request an independent external review through their state's Independent Review Organization (IRO). The IRO decision is binding on Anthem. State insurance departments oversee this process, and the timeline varies by jurisdiction but typically takes 30 to 45 days for standard reviews.

Three practical tips for a successful appeal: submit all supporting documentation with the initial appeal rather than in pieces, request that the prescribing endocrinologist write a peer-to-peer letter rather than relying on a general practitioner's notes, and reference specific ADA Standards of Care language about individualized insulin therapy 5.

Cost-Reduction Strategies for Lantus on Anthem Plans

The gap between Lantus's $340 monthly list price and what a patient actually pays depends on several overlapping discount mechanisms. Patients on Anthem plans have multiple pathways to reduce out-of-pocket costs.

Sanofi's Lantus Savings Card offers eligible commercially insured patients a copay as low as $0 per prescription for up to 10 pens or vials per fill. The savings card covers the difference between the patient's plan copay and the promotional price, up to a maximum annual benefit. Patients with government insurance (Medicare, Medicaid, Tricare) are not eligible for the manufacturer card 8. Sanofi also participates in the Insulins.com platform, offering a cash-pay option at $35 per month for patients who prefer to bypass insurance entirely.

The Inflation Reduction Act (IRA) capped insulin copays at $35 per month for Medicare Part D enrollees beginning January 2024 9. While this federal cap applies only to Medicare, several Anthem commercial plans have voluntarily adopted similar $35 insulin copay caps for their commercial members. Patients should check whether their specific Anthem plan participates in a voluntary insulin cost-sharing cap.

For patients whose Anthem plan imposes high coinsurance on Tier 3 drugs, switching to a preferred biosimilar at Tier 2 is the most direct cost reduction. Semglee and Rezvoglar deliver the same active molecule (insulin glargine, 100 units/mL) and have demonstrated bioequivalence to Lantus in clinical studies reviewed by the FDA 8. A 2021 analysis found that biosimilar insulin glargine products were priced 30% to 65% below the branded reference product at wholesale acquisition cost 10.

Lantus vs. Biosimilar Insulin Glargine: Clinical Considerations

The clinical question behind Anthem's step therapy requirement is whether biosimilar insulin glargine performs identically to Lantus for every patient. The pharmacologic answer is yes, with caveats.

FDA-approved biosimilars must demonstrate no clinically meaningful differences from the reference product in pharmacokinetics, pharmacodynamics, safety, and efficacy 8. The INSTRIDE studies comparing biosimilar insulin glargine to Lantus showed equivalent A1C reduction and comparable hypoglycemia rates across patient populations 11. In INSTRIDE 1, which enrolled 558 patients with type 1 diabetes, the biosimilar achieved a mean A1C change of -0.14% compared to -0.11% for Lantus at 52 weeks, a difference within the predefined equivalence margin.

The caveats are practical, not pharmacologic. Pen devices differ between products. Patients with dexterity issues, vision impairment, or established muscle memory for a specific pen mechanism may struggle with a device switch. These device-related concerns are legitimate grounds for a step therapy exception request.

Dr. Anne Peters, professor of clinical medicine at the Keck School of Medicine of USC, has stated: "Biosimilar insulins are clinically equivalent, but the act of switching itself can cause anxiety and confusion that leads to dosing errors, particularly in elderly patients and those with limited health literacy" 12. This perspective supports careful transition management when a plan requires a formulary switch.

Anthem Coverage for Special Populations

Anthem's coverage rules for Lantus differ across plan types and patient categories. Pediatric patients with type 1 diabetes, pregnant patients with gestational or pre-existing diabetes, and patients on insulin pump therapy each face specific coverage considerations.

For pediatric patients, Lantus received FDA approval for use in children aged 6 years and older with type 1 diabetes 2. Anthem generally applies the same PA and step therapy requirements to pediatric patients, though prescribers can argue for a step therapy override based on the greater risk of hypoglycemia in children and the importance of device familiarity. A 2019 retrospective study found that non-medical insulin switching in pediatric type 1 diabetes patients was associated with a 0.3% increase in A1C over six months 13.

Pregnant patients represent another exception pathway. The ADA recommends that insulin-treated patients entering pregnancy continue their current insulin regimen if glycemic control is adequate 5. Anthem typically grants step therapy overrides for pregnant patients already stabilized on Lantus, recognizing that glycemic disruption during pregnancy carries risks of macrosomia, preeclampsia, and neonatal hypoglycemia.

Patients using Lantus in combination with rapid-acting insulin (basal-bolus therapy) or with GLP-1 receptor agonists should ensure that their PA documentation reflects the complete regimen. Anthem may require separate PAs for each injectable component. The fixed-ratio combination Soliqua (insulin glargine/lixisenatide) has its own formulary placement distinct from standalone Lantus 14.

Anthem Medicaid and Medicare Advantage Plans

Anthem's Medicaid managed care and Medicare Advantage plans operate under different formulary rules than commercial plans. These distinctions affect Lantus coverage, cost-sharing, and appeal timelines.

Anthem Medicare Advantage (MA) plans must comply with the CMS Part D formulary requirements. Under the Inflation Reduction Act, all Medicare Part D plans, including Anthem MA-PD plans, cap insulin cost-sharing at $35 per month per covered insulin product 9. This cap applies regardless of formulary tier. Medicare patients on Anthem MA plans still face PA and step therapy edits, but the financial impact of tier placement is neutralized by the $35 cap.

Medicaid managed care formularies vary by state. Anthem operates Medicaid plans under various state contracts (e.g., Anthem Blue Cross in California, Anthem Blue Cross Blue Shield in multiple states). Federal Medicaid rules require coverage of all FDA-approved drugs from manufacturers that participate in the Medicaid Drug Rebate Program, which includes Sanofi 15. States can impose preferred drug lists and prior authorization, but cannot exclude Lantus from coverage entirely if the prescriber documents medical necessity.

The appeal timeline for Medicaid denials is shorter than for commercial plans. Federal regulations require Medicaid managed care plans to resolve standard appeals within 30 days and expedited appeals within 72 hours. Patients who disagree with the appeal outcome can request a state fair hearing, a right unique to Medicaid that does not exist in commercial insurance.